¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Polymorphism, Single Nucleotide"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
single nucleotide polymorphism
´ÜÀÏ´ºÅ¬·¹¿ÀƼµå´ÙÇüÅÂ
diphosphopyridine nucleotide
ÀÌÀλêÇǸ®µò´ºÅ¬·¹¿ÀƼµå
nucleotide
´ºÅ¬·¹¿ÀƼµå
polymorphism
´ÙÇüÅÂ, ¹µÇüÅÂ, ¿©·¯ÇüÅÂ
restriction fragment length polymorphism
Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
multitarget single hit model
´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
single atrium
Ȭ½É¹æ, ´Ü½É¹æ
single blind study
´ÜÀϸͰ˿¬±¸
single burst
ÀÏȸ¹æÃâ·®
single colony isolation
´ÜÀÏÁý¶ôºÐ¸®, Áý¶ô°í¸£±â
single donor platelet
ÀÏÀÎÇåÇ÷ÀÚÇ÷¼ÒÆÇ, ÀÏÀΰøÇ÷ÀÚÇ÷¼ÒÆÇ
single immunodiffusion
´ÜÀϸ鿪Ȯ»ê
single injection technique
ÀÏȸÁÖÀÔ¹ý
single interference pattern
´ÜÀϰ£¼·¾ç»ó
single investing method
ÀÏȸ¸Å¸ô¹ý
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
nucleotide
´ºÅ¬·¹¿ÀƼµå
polymorphism
´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
single blinding study
´Ü¼ø¸Í°Ë¹ý
single vision
´ÜÀϽÃ
single ventricle
´Ü½É½Ç, Ȭ½É½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
polymorphism
´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
restriction fragment length polymorphism
Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
complementary nucleotide
»óº¸´ºÅ¬·¹¿ÀƼµå
diphosphopyridine nucleotide
ÀÌÀλêÇǸ®µò´ºÅ¬·¹¿ÀƼµå
nucleotide
´ºÅ¬·¹¿ÀƼµå
single atrium
Ȭ½É¹æ, ´Ü½É¹æ
single burst
ÀÏȸ¹æÃâ·®
single-agent chemotherapy
´ÜÀÏÁ¦Á¦Ç×¾ÏÈÇпä¹ý
single-step growth curve
ÀÏȸÁõ½Ä°î¼±
single fiber electrode
´ÜÀϼ¶À¯Àü±Ø
single outlet heart
´ÜÀÏÀ¯Ãâ·Î½ÉÀå
single immunodiffusion
´ÜÀϸ鿪Ȯ»ê
single colony isolation
´ÜÀÏÁý¶ôºÐ¸®, Áý¶ô°í¸£±â
single linkage
´ÜÀÏ¿¬¼â
multitarget single hit model
´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
9
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
SPECT, see single positron emission computed tomopraphy
½ºÆåÆ®(´ÜÀϾçÀÚ¹æÃâÀü»êÈ´ÜÃþÃÔ¿µ¼ú)
growth curve, single-step
ÀÏȸÁõ½Ä°î¼±
DNA polymorphism
DNA ´ÙÇü¼º
polymorphism
´ÙÇüÁõ
polymorphism
´ÙÇüÁõ(Òýû¡à÷ñø)
polymorphism
´ÙÇü¼ºÁõ
polymorphism
´ÙÇü, ´ÙÇüÅÂ
polymorphism
´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
polymorphism
´ÙÇü¼º(Òýúþàõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
diphosphopyridine nucleotide =DPN
ÀÌÀλêÇǸ®µò ´©Å¬·¹¿ÀƼµå.
nicotinamide adenine nucleotide
´ÏÄÚÆ¾¾Æ¹Ìµå¾Æµ¥´Ñ´©Å¬·¹¿ÀƼµå
nucleotide
´ºÅ¬·¹¿ÀŸÀ̵å
nucleotide
´©Å¬¸®¿ÀŸÀÌ.
triphosphopyridine nucleotide
»ïÀλêÇǸ®µò´©Å¬·¹¿ÀƼµå.
pharmacogenetic polymorphism
¾à¹°À¯ÀüÇÐÀû ´ÙÇü¼º.
polymorphism
´ÙÇü, ´ÙÇüÅÂ
polymorphism
´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
polymorphism
´ÙÇü¼º(Òýúþàõ)
polymorphism
´ÙÇüÁõ
polymorphism
´ÙÇüÁõ(Òýû¡à÷ñø)
polymorphism
´ÙÇü¼ºÁõ
restriction fragment length polymorphism
Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡Òýû¡à÷)
restriction fragment length polymorphism,in cystic fibrosis
³¶¼º¼¶À¯Áõ(ÀÇ)¡(Ò¥àõàéë«ñø¡)
restriction fragment length polymorphism analysis
Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½